Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) has unveiled its financial results for the quarter ending June 30, 2024, highlighting a robust start to the fiscal year. The company’s revenue surged by 18% year-on-year (YoY), accompanied by a substantial expansion in gross margins and significant increases in both EBITDA and profit after tax (PAT). […]
Indian pharmaceutical powerhouse, Marksans Pharma has achieved a significant milestone, securing the coveted US Food and Drug Administration (FDA) nod for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets in both 600 mg and 1200 mg concentrations. These breakthrough tablets are confirmed to be bioequivalent to the acclaimed Mucinex Extended-Release Tablets of the […]
Marksans Pharma said that it has been granted final approval for the over-the-counter (OTC) use of Famotidine Tablets USP, 10 mg and 20 mg from the US Food and Drugs Administration (FDA). Famotidine Tablets is bioequivalent to Pepcid AC tablets, said the India-based pharma company. The reference listed drug (RLD) is owned by Johnson & […]